Drug Eluting Stents and Beyond

Author(s): Ashish Rastogi, Salomon Stavchansky

Journal Name: Current Pharmaceutical Design

Volume 14 , Issue 21 , 2008

Become EABM
Become Reviewer
Call for Editor


The present review discusses the mechanism of late stent thrombosis and its distinction from restenosis and summarizes the advisory note issued by FDA on the proper usage of different treatments available for atherosclerosis. In light of the latest developments, a plethora of new stents have been and continue to be developed globally. Hence, there is a need to review the available methodology to control their quality and to understand the delivery of drugs to the lesion. This can be achieved by systematically reviewing the novelties in each type. The article evaluates upcoming drugs, biocompatible coatings, and new concepts. We have also provided the latest update on the three new promising drug eluting stents (DES) – Medtronics Endeavor, Abbotts Xience, and Conor Medsystems CoStar. In addition, the article also summarizes other DES in horizon.

Keywords: Drug eluting stents, bare metal stents, restenosis, late stent thrombosis, polymers

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [2111 - 2120]
Pages: 10
DOI: 10.2174/138161208785294573
Price: $65

Article Metrics

PDF: 5